Traditional in vitro assays often fail to recapitulate the complexity of in vivo inflammatory processes, whereas mammalian models are costly, time-consuming, and poorly suited to large-scale screening (Bernardette Martinez-Rizo et al., 2024
Dihexa has not received FDA approval for any medical condition
We next optimized a NRF2 transcriptional signature resulting in a set of 59 genes based on their contribution to the model and overlap with previously reported NRF2 signatures (Figs
PR Newswire Additional Phase 3 readouts covering cardiovascular outcomes, MASLD histology, sleep apnea, and chronic pain indications are expected throughout 2026
Yang S, Gao Y, Liu G, Li J, Shi K, Du B, et al
The Influence of a Novel Pentadecapeptide, BPC 157, on N(G)-nitro-L-argininemethylester and L-Arginine Effects on Stomach Mucosa Integrity and Blood Pressure